Aflibercept in exudative age related macular degeneration refractory to ranibizumab

详细信息    查看全文

• 作者：J. Ruiz Ramos^a ; ^{jrzrms@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; I. Pascual-Camps^b ; M.J. Cu&eacute ; llar-Monreal^a ; R. Dolz-Marco^b ; M.A. Fenoll^b ; I. Font-Noguera^a ; J.L. Poveda-Andr&eacute ; s^a ; R. Gallego-Pinazo^b
• 关键词：Aflibercept ; Ranibizumab ; Macular degeneration ; Cost-effectiveness ; Visual acuity
• 刊名：Archivos de la Sociedad Española de Oftalmología (English Edition)
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：90
• 期：12
• 页码：566-571
• 全文大小：512 K

文摘

The aim of this study is to determine the effectiveness, safety and cost of aflibercept in the treatment of wet age-related macular degeneration (ARMD) refractory to ranibizumab.

Methods

Retrospective observational study was conducted on patients diagnosed with wet ARMD, and previously treated with ranibizumab. Efficacy variables assessed were changes in visual acuity (BCVA) and anatomical improvements in the most affected eye. Factors associated with improvement of BCVA with aflibercept were also studied. Adverse events related to the aflibercept administration were recorded. Cost analysis data were collected from the hospital perspective, and only taking the direct medical costs into account. Cost-effectiveness analysis was calculated using the aflibercept treatment cost, and effectiveness calculated as BCVA gained.

Results

A total of 50 eyes corresponding to 46 patients were included. The median follow-up period was 4.6 months (range: 1.0–6.0). Improvement in visual acuity after the first 2 doses and at the end of the follow-up period was observed in 32.0 and 28.0% of treated eyes, respectively. None of the variables studied was associated with an improvement in the BCVA after treatment. No significant differences were found in the average monthly cost between treatments.

Conclusions

Aflibercept is shown to be an effective treatment in a significant number of patients resistant to treatment with ranibizumab, presenting a cost similar to that generated during the final stages of treatment with ranibizumab.